FDA Woodcock Calls for HHS OIG Investigation Into Aduhelm Approval Thomas Sullivan Sep 7, 2021 0 After the controversial FDA approval of Aduhelm, Biogen’s Alzheimer’s disease therapy, the agency’s acting commissioner is calling…
